2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1450

Clostridium Difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1109

Co-Crystal Structure of TACI and APRIL-BAFF-BAFF Heteromer Suggests That Charged Residues in APRIL and BAFF Dictate Their Receptor Binding Affinities

B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 1408

Cogan Syndrome: Differential Response to Biologic Agents and Role of PET-CT in the Increased Diagnosis of Aortitis

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1153

Colonic Intraepithelial Lymphocytes Produce IL-6 in Response to Resident Bacteria to Modulate Epithelial Barrier Function

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1959

Color Doppler Ultrasonography Appears to Perform Better Than Magnetic Resonance Angiography in the Diagnostics of Patients with Systemic Large Vessel Vasculitis

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1957

Colour-Doppler Ultrasonography of Epiaortic Arteries in Patients with Giant Cell Arteritis

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1707

Comorbidity Burden and Medication Use Among Patients with Psoriatic Arthritis in the US

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1781

Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1486

Comparative Study of Instruments to Assess Disease Activity in Fibrolyalgia

Quality Measures and Quality of Care Poster Session (ARHP): Clinical Practice/Patient Care

9:00AM-11:00AM: Abstract Number: 1300

Comparison Between Semiquantitative and Quantitative Methods for the Assessment of Knee Synovitis Using Non-Enhanced and Gadolinium-Enhanced MRI

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1548

Comparison of 5 Cardiovascular Risk Calculators in a Hispanic Rheumatoid Arthritis Cohort

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1819

Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1280

Comparison of Health Service Utilization Costs Between Aboriginal and Non-Aboriginal Patients with Rheumatoid Arthritis Requiring Biologic Therapy

Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

9:00AM-11:00AM: Abstract Number: 1384

Comparison of IgG4-Related and Non-IgG4-Related Retroperitoneal Fibrosis; A 12 Year Retrospective Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1478

Comparison of JIA and RA Patients in the National Data Bank for Rheumatic Diseases

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].